Progression-free survival was slightly , but significantly , improved in the ombrabulin group compared with the placebo group ( median 154 months [ 95 % CI 145-269 ] vs 141 [ 138-158 ] months ; hazard ratio 076 [ 95 % CI 059-098 ] ; p = 00302 ) .